69 Scientists have developed an innovative drug delivery system using attapulgite microspheres coated with poly(lactic acid-glycollic acid) nanoparticles to improve the efficacy and safety of chemotherapy for bone cancer patients. This system not only enhances the targeted delivery of doxorubicin, a common chemotherapy drug, but also reduces its associated toxicity. The findings were published in the Journal of Drug Delivery Science and Technology. Bone cancer, characterised by its high metastatic potential and resistance to conventional treatments, has long posed a challenge for oncologists. The five-year survival rate remains low, primarily due to the cancer’s insensitivity to radiation and the toxic side effects of systemic chemotherapy. Addressing these challenges, the new drug delivery system offers a promising solution by introducing sustained and controlled drug release. The core of this system lies in the use of attapulgite microspheres (ATT-MS), a naturally occurring magnesium aluminium silicate with excellent drug-loading capabilities. These microspheres are coated with nano-poly(lactic acid-glycollic acid) (nano-PLGA) particles, forming a unique satellite-like structure. This design facilitates the gradual release of doxorubicin specifically in the tumour microenvironment, where the pH is slightly acidic. In contrast, drug release is significantly slower in normal tissues, minimising side effects. Key experiments demonstrated that this system achieves a high drug encapsulation efficiency of 98%, ensuring minimal drug loss during delivery. The coating of nano-PLGA particles provides an additional layer of control, allowing the system to respond to the unique conditions of tumour tissues. When tested in vivo, the delivery system not only inhibited tumour growth but also reduced damage to vital organs such as the heart and kidneys, which are typically affected by free doxorubicin. The mechanism underlying the system’s efficacy lies in its ability to exploit the tumour’s acidic environment. Under these conditions, the PLGA coating breaks down, releasing doxorubicin directly into the tumour cells. This targeted approach maximises the drug’s impact on cancer cells while sparing healthy tissues. Moreover, the system’s design reduces the risk of rapid drug release, a common issue with traditional delivery methods that can lead to toxicity. Safety and compatibility were key considerations in the development of this system. Cytotoxicity tests confirmed that the materials used, including attapulgite and PLGA, are safe for human cells. Additionally, the system passed rigorous haemolysis tests, indicating it does not damage red blood cells upon entering the bloodstream. This novel approach addresses two critical issues in cancer therapy: the need for effective targeting and the reduction of systemic side effects. By delivering drugs more precisely and sustainably, the system holds promise for improving the quality of life for patients undergoing chemotherapy. While the technology is still in its experimental stages, researchers are optimistic about its potential. Future studies aim to refine the system further and explore its application to other types of cancer. If successful, this drug delivery innovation could mark a significant step forward in oncology, offering new hope for patients battling this devastating disease.